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In a companion article, we describe the engineering and characterization of pituitary GH3 cell clones stably 
transfected with a furin-cleavable human insulin cDNA (InsGH3 cells). This article describes the perfor­
mance of InsGH3 (clones 1 and 7) cell grafts into streptozotocin (STZ)-induced diabetic nude mice. Subcuta­
neous implantation of 2 x 106 InsGH3 cells resulted in the progressive reversal of hyperglycemia and diabetic 
symptoms, even though the progressive growth of the transplanted cells (clone 7) eventually led to glycemic 
levels below the normal mouse range. Proinsulin transgene expression was maintained in harvested InsGFG 
grafts that, conversely, lose the expression of the prolactin (PRL) gene. Elevated concentrations of circulating 
mature human insulin were detected in graft recipients, demonstrating that proinsulin processing by InsGH3 
cells did occur in vivo. Histologic analysis showed that transplanted InsGH3 grew in forms of encapsulated 
tumors composed of cells with small cytoplasms weakly stained for the presence of insulin. Conversely, 
intense insulin immunoreactivity was detected in graft-draining venules. Compared to pancreatic pTC3 cells, 
lnsGH3 cells showed in vitro a higher rate of replication, an elevate resistance to apoptosis induced by 
serum deprivation and proinflammatory cytokines, and significantly higher antiapoptotic Bcl-2 protein levels. 
Moreover, InsGH3 cells were resistant to the streptozotocin toxicity that, in contrast, reduced PTC3 cell 
viability to 50-60% of controls. In conclusion, proinsulin gene expression and mature insulin secretion 
persisted in transplanted InsGH3 cells that reversed hyperglycemia in vivo. InsGH3 cells might represent a 
potential P-cell surrogate because they are more resistant than pancreatic p cells to different apoptotic insults 
and might therefore be particularly suitable for encapsulation. 
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INTRODUCTION 
Diabetes cell therapy depends on the implantat ion of 
insul in-producing cells in sufficient number and quality 
to survive long enough to restore the pancreat ic endo­
crine function and to escape from au to immune recogni­
tion. Recent improvements in the field of immunoisola­
tion membranes , which allow transplantation in the 
absence of systemic immunosuppress ion (6), gave impe­
tus to search for xenogeneic islets (19) or P-cell lines 
(2-4 ,6 ,7 ,15 ,16 ,20 ,24 ,28 ,33) for encapsulat ion-based di­
abetes cell therapy. Encapsulated cells must be supplied 
with oxygen and nutrients by diffusion from the closest 
b lood vessels , surrounding tissue, and immunoisola t ion 
membrane . The distance from the nearest b lood vessels 
determines a gradient in oxygen and nutrients supply 
that is often unbearable for the p cells (6), which are 
normal ly extremely well perfused (3). Indeed, P-cell se­
cretion and viability are extremely susceptible to hy­
poxia and other cytotoxic stresses (12,21,29) . Immedia te 
loss of islet t issue, as a result of oxygen supply limita­
tion and aspecific inflammation, has also been shown in 
naked syngeneic transplantation (8). 
P-cell vulnerabil i ty, as well as p-cell-directed cyto­
toxicity present in au to immune diabetes, raises the ra­
tionale of using non-p cells for diabetes cell therapy. 
Previous studies suggested that G H 3 cells might b e a 
logical substrate for engineer ing an artificial P cell, even 
though they express the receptor- type protein tyrosine 
phosphatase IA-2a (36), which is an islet autoantigen of 
type I diabetes (32). Indeed, a cytotoxic antibody that 
b inds to rat pancreat ic islet cells and R I N cells, but not 
to G H 3 cells, has been described in the N O D m o u s e 
(31). Moreover , splenic lymphoid cells cytotoxic to ma­
jo r histocompatibi l i ty complex (MCH)-compat ib le 
Wistar-Furth rat islets and also to MCH- incompa t ib l e 
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Lewis rat islets and R I N cells, but not to G H 3 cells, 
have been described in diabetic B B rats (26). In addi­
tion, cytotoxic cel l -mediated immunoreact iv i ty selec­
tively against a P-cell line was also observed in the mul ­
tiple low-dose s t reptozotocin-induced rodent model of 
au to immune diabetes (27). 
The rationale of developing insulin-secreting non-P 
cells also applies to encapsulat ion. Indeed, shed P-cell 
ant igens might foster an inf lammatory reaction around 
the capsule , leading to per icapsular fibrosis and suffoca­
tion of encapsulated cells (6). Fur thermore , shed anti­
gens from encapsulated P cells might perpetuate or reac­
tivate auto immuni ty against the residual rec ip ient ' s 
pancreat ic P cells that often survive for years after the 
diagnosis of type I diabetes . G H 3 cells are also attractive 
because their original secretory products (rat prolactin 
and growth hormone) do not exert biological effects on 
human tissues due to the species specificity of the hu­
m a n receptors (18,37) , even though their secretory prod­
ucts might still be immunogen ic . Finally, xenogeneic 
InsGFD cells, be ing highly phylogenet ical ly distant, 
should be prompt ly rejected in case of leakage from en­
capsulat ion devices, thereby minimiz ing the safety con­
cerns related to the use of t ransformed cell l ines into 
humans . 
In this study we explored the performance of insulin-
secreting pituitary G H 3 cell ( InsGFB cells, described in 
a companion article, this issue) implants performed in 
STZ-diabet ic mice . W e also compared the vulnerabili ty 
of InsGFB and PTC3 cells to a variety of toxic agents . 
Our data indicate that In sGFB cells might be a potential 
P-cell surrogate for encapsulat ion-based cell therapy 
even though addit ional engineer ing is required. 
M A T E R I A L S A N D M E T H O D S 
Cells and Cell Cultures 
Rat pituitary G H 3 (Amer ican Type Cul ture Col lec­
t ion), m o u s e pancreat ic P T C 3 cells, and proinsulin-
transfected I n s G H 3 cells (clones 1 and 7) were cul tured 
as previously described in the companion article. 
Cell Growth In Vitro 
Proliferation was determined by cell count ing with a 
Coulter Counter Z M (Beckman, Coulter Inc., CA, USA) . 
I n s G H 3 (clones 1 and 7) , wild- type G H 3 , and p T C 3 
cells were plated onto six mult iwell plates and cultured 
under standard condi t ions. Cells were then harvested 
and counted 2, 4 , 6, and 8 days after plating. 
Detection of Apoptosis 
Apoptos is was determined by using a D N A fragmen­
tation assay (13). Briefly, In sGH3 cells of both clones 
and p T C 3 cells ( < 5 0 % confluent) cul tured for 5 days in 
25 -cm 2 t issue culture flask in their standard tissue cul­
ture med ium supplemented or not with 10% FCS , or in 
the presence of a cocktail of cytokines (IL-1 50 IU/ml + 
T N F - a 1000 Ul /ml + IFN-y 1000 Ul /ml) were washed 
and resuspended in 100 pi of lysis buffer (10 m M 
Tris -HCl/10 m M E D T A / 0 . 5 % Triton X-100, pH 8.0) 
and sonicated. After centrifugation for 20 min at 4°C 
(14,000 xg), the supernatant-containing fragmented 
(soluble) D N A was transferred to another tube. Lysis 
buffer (100 p i ) was added to the pellet containing insol­
uble D N A . Samples were then treated with Rnase for 1 
h and then with proteinase-K for another hour. After 
adding isopropanol , samples were incubated overnight 
at - 2 0 ° C , and the D N A concentrat ions were measured 
by the method of Duke and Sellins (13). Fragmented 
D N A was calculated as 100% x soluble DNA/so lub le + 
insoluble D N A . The soluble fraction of D N A was deter­
mined by electrophoresis on 1.8% agarose gel. 
MTT Viability Assay 
Viability of In sGH3 (clones 1 and 7) and p T C 3 cells 
cultured 5 days in the presence of the same mixture of 
cytokines descr ibed above, or exposed for 1 h to increas­
ing concentrat ions of streptozotocin (2 and 10 m m o l / L ; 
Sigma, St. Louis , M O ) , was measured by using the M T T 
(tetrazolium) colorimetric assay (22). 
Western Blotting 
Bcl-2 protein levels in P T C 3 , G H 3 wild- type, and 
I n s G H 3 clones were measured by Weste rn blott ing and 
anti-Bcl-2 antibody (rabbit anti goat 1:100; Santa Cruz , 
Biotechnology, U S A ) . 
Insulin Assays 
Circulat ing insulin levels in mice bear ing I n s G H 3 
grafts were measured by using a I R M A ( S A N O F I , 
Pasteur Institute, Paris, France) , which recognizes only 
human mature insulin and split 65-66, and does not 
cross-react with the other (pro)insulin forms. Circulat ing 
human proinsulin levels were measured by E L I S A 
(Dako Diagnost ic , Ely, UK) , which does not cross-react 
with insulin and other split proinsulin forms. H u m a n C-
pept ide levels were measured by RIA (Diagnost ic Prod­
uct Corporat ion, LA, U S A ) . 
Transplantation Experiments 
Male nude mice (Nu/Nu, 6 - 8 weeks old) were ren­
dered diabetic by injecting a single dose of S T Z (180 
mg/kg body weight , IP). Diabetes was confirmed by the 
presence of hyperglycemia (>350 mg/dl ) , weight loss, 
and polyuria . R a n d o m (nonfasted) g lycemic levels were 
measured (between 0900 and 1000 h) on whole blood 
obtained from the snipped mouse tail with a portable 
glucose meter (One Touch II, Johnson & Johnson, Mil -
pitas, CA) . T h e animals were kept under conventional 
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condi t ions in cl imatized rooms with free access to water 
and food. Three groups of diabetic mice were implanted 
subcutaneously be tween the shoulders with aliquots of 2 
x 10 6 wi ld- type G H 3 cells and InsGH3 cells of clones 1 
and 7. After implantation, mice were fol lowed with re­
peated measurements of blood glucose levels and body 
weight . At the t ime of sacrifice grafts were retrieved and 
R N A was extracted for the analysis of proinsulin trans­
gene expression by Northern blott ing analysis . Naive 
pancreases were also harvested and immunosta ined for 
insulin as previously descr ibed (9) in order to detect re­
sidual P cel ls . Finally, b lood samples were collected for 
the measurement of circulating mature human insulin 
levels. T o determine proinsulin process ing by trans­
planted InsGH3 cells, circulating human insulin, proin­
sulin, and C-pept ide levels were measured in the s ame 
samples d rawn from normal nude mice that were trans­
planted 2 weeks earlier with 2 x 10 6 InsGH3/c lone 7. 
Northern Blot Analysis 
At the t ime of sacrifice the grafts were harvested and 
divided into two parts . One half of each graft was used 
to measure the expression of the human proinsulin and 
rat P R L genes in either wild-type G H 3 or I n s G H 3 cell 
implants . Immedia te ly after harvest ing, total graft R N A 
was prepared with the U L T R A S P E C R N A isolation sys­
tem (Biotecx Laborator ies Inc., Houston, TX) . Northern 
blot analysis was performed as described in the compan­
ion article (this issue). 
Graft Morphology and Immunohistochemistry 
The second half of the harvested grafts (wild-type 
G H 3 and InsGH3 implants) underwent histologic analy­
sis. Morphology and immunohis tochemis t ry were per­
formed on formalin-fixed, paraff in-embedded speci­
mens . After deparaffinization and rehydrat ion, 5 -pm 
sections were stained with hematoxyl in-eosin and im­
munos ta ined for insulin (guinea pig anti-porcine 1:1500; 
Eurodiagnost ica , M a l m o , Sweden) . Slides were blocked 
for 30 min in 5 % normal goat serum and 0 . 1 % Triton 
X-100 in phosphate-buffered saline (PBS) and exposed 
overnight to the pr imary ant ibodies. Sections were then 
washed and incubated with the secondary ant ibodies for 
1 h at room temperature . The specific staining was de­
tected using the A B C immunoperoxidase system (Vec-
tastatin, Vector, Bur l ingame, C A ) as chromogen . 
In Situ Hybridization 
Graft specimens were cleared of paraffin with xylene 
and rehydrated by sequential washings with graded etha­
nol solut ions ( 7 0 - 9 5 % ) . After three washes in PBS 
buffer, sections were deproteinated by incubation (20 
min, room temperature) with proteinase K (10 pg /ml ) in 
10 m M Tris buffer, pH 7.5, containing 2 m M CaCl 2 . 
Deproteinated t issues were r insed in 2 x S S C for 10 min 
and then prehybridized for 3 h at room temperature with 
prehybridizat ion buffer ( 5 0 % formamide, 4 x SSC, 2x 
Denhard t ' s , 0 . 1 % S D S , 100 pg /ml sa lmon sperm D N A ) . 
Hybridizat ion was performed with 8 ng/p l of proinsulin 
digoxigenin- labeled R N A probe (sense or antisense) in 
hybridizat ion solution (i.e., prehybridizat ion buffer with 
10% dextran sulfate). Slides were covered with parafilm 
and incubated at 42°C for 16 h in a humidif ied chamber . 
After hybridization, sections were washed twice in 4 x 
S S C and then incubated with Rnase A (50 pg /ml ) for 30 
min at 3°C. Posthybridizat ion t reatment was performed 
by incubation of sections in 2x SSC, 0 . 1 % S D S (twice 
for 15 min/each) , 2x S S C (15 min) , l x S S C (15 min) . 
T o detect digoxigenin-labeled probe, tissue was rinsed 
briefly in T B S buffer, b locked for 7 h in 100 m M Tr is -
HCl , p H 7.5, 150 m M NaCl , 1% B S A , and 0 . 3 % Triton 
X-100 and then incubated with an ant i-digoxigenin 
ant ibody, conjugated to alkal ine phosphatase (Boeh­
ringer Mannhe im) , diluted 1:400. T h e specific signals 
were visualized by incubation in developing buffer (100 
m M Tris -HCl , pH 9.5, 100 m M NaCl , and 50 m M 
M g C l 2 ) , containing 0.34 mg/ml of ni trotetrazolium blue, 
0.17 mg/ml of 5-bromo-4-chloro-3-indolylphosphate, and 
0 .024% levamisole . Developing reaction was stopped 
with 10 m M Tr is -HCl , p H 7 .5; sect ions were dehydrated 
with graded ethanol solutions ( 7 0 - 9 5 % ) and mounted . 
Statistical Analysis 
Exper iments were repeated at least three t imes. Da ta 
were expressed as means ± SE. Statistical analysis was 
performed using the unpaired S tuden t ' s Mest for pair-
wise compar i sons and one- or two-way analysis of vari­
ance ( A N O V A ) for mult iple compar isons . Statistical 
significance was considered at p < 0 .05. 
R E S U L T S 
Cell Growth 
As shown in Figure 1, I n s G H 3 cells of c lones 1 and 
7 proliferated in vitro significantly faster than wild- type 
G H 3 and pTC3 cells (p < 0.01 at day 7 and p < 0.001 at 
day 9 vs. G H 3 and pTC3). PTC3 cells grew with the 
longest doubl ing t ime (approximately 68 vs. 24 h of 
In sGH3 clones) and reached a maximal density of 4.4 x 
10 4 ce l l /cm 2 , which was about 10-fold lower than the 
maximal density of I n s G H 3 clone 7 ( 1 . 4 x l 0 5 cells/ 
c m 2 ) . 
Apoptosis 
Both InsGH3 clones were extremely resistant to 
apoptosis induced by se rum deprivat ion and proinflam­
matory cytokines . In In sGH3 cells no evidence of D N A 
fragmentation was detected after 5 days of cul ture in the 
absence of serum, whi le mass ive apoptosis was detected 
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Figure 1. Cell replication in vitro. Proliferation of InsGFB cells (clones 1 and 7), with a doubling 
time of about 24 h, was significantly higher than that of wild-type GH3 and (3TC3 cells (*p < 0.01 
at day 7, and #p < 0.001 at day 9 vs both GH3 and |3TC3). (3TC3 showed the lowest replication 
rate with an approximate doubling time of 68 h. Data are mean ± SE of six independent experi­
ments, performed in duplicate. 
in (3TC3 cells (Fig. 2, top) . In In sGH3 cells of c lone 
1, serum deprivation increased D N A laddering from a 
basel ine of 0 .02% to 0 .4%, and in InsGFD of c lone 7 
from 0 . 0 1 % to 0 . 5 % ; in contrast , in PTC3 cells basel ine 
laddering was 0 .4% that increased to 2 4 % in the absence 
of serum (Fig. 2, bo t tom) . InsGFD cells (clones 1 and 
7) were also more resistant than PTC3 to apoptosis in­
duced by proinf lammatory cytokines . The percentage of 
fragmented D N A after exposure to cytokines was 9.8% 
in InsGFD clone 1, 5 .5% in InsGFD clone 7, and 3 0 % 
in PTC3 cells (Fig. 3). 
MTT Viability Assay 
This test measured the reduction of tetrazolium salt 
into insoluble colored formazan crystals. Exposure of 
InsGFD (clones 1 and 7) to 2 and 10 m m o / L S T Z did 
not induced any significant decrease in formazan pro­
duction, thereby indicating the absence of cytotoxicity. 
In contrast, 2 m m o l / L S T Z induced a 5 5 % decrease in 
formazan product ion by PTC3 cells, indicating a mas­
sive loss in PTC3 viability that did not decreased any 
further at 10 mmol /L S T Z (Fig. 4) . 
A five-day exposure of InsGFD (clones 1 and 7) and 
PTC3 cells to the same mixture of proinflammatory cy­
tokines utilized for the induction of apoptosis resulted in 
a decreased viability of PTC3 and InsGFD cells (clones 
1 and 7) to 51 ± 1 1 % , 6 2 + 1 1 % , and 57 ± 10% of con­
trols, respectively (NS). 
Bcl-2 Protein Levels 
Western blott ing exper iments showed the absence of 
measurable Bcl-2 protein in PTC3 cells. In contrast , 
Bcl-2 protein was abundant in wild-type G H 3 cells and 
in InsGFD of both clones even though it was signifi­
cantly higher in c lone 1 than in c lone 7 and in wild- type 
G H 3 cells (Fig. 5) . 
Transplantation Experiments 
Results of subcutaneous implantat ion of wild- type 
G H 3 and InsGFD cells (clones 1 and 7) into diabetic 
nude mice are shown in Figure 6. Similar with all 
c lones, implanted cells grew tumors that remained con­
fined to the site of implantation and that, 5 weeks after 
implantation, had an average d iameter of about 6 - 7 mm. 
Mice transplanted with wild-type G H 3 cells remained 
hyperglycemic and were sacrificed 5 weeks after im­
plantation with blood glucose levels of 435 ± 23 mg/dl , 
undetectable circulating human insulin, and a gain in 
body weight of 1.9 ± 0.4 g. In contrast , mice implanted 
with InsGLD cells of c lone 7 showed rapid reversal of 
the diabetic symptoms and a progressive decrease of 
blood glucose levels that, 5 weeks after transplantation, 
were be low normal range (72 ± 3 mg/dl) . Because of the 
risk of severe hypoglycemia consequent to additional tu­
mor growth, recipients of this group were sacrificed 5 
weeks after implantat ion; at that t ime mice were heal thy, 
with a mean level of circulating human mature insulin 
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Figure 2. Apoptosis induced by serum deprivation. Upper 
panels show two representative gels of DNA extracted from 
InsGFD cells (clones 1 and 7) (left) and pTC3 cells (right) 
cultured for 5 days in the absence of serum. DNA fragmenta­
tion, typical of apoptosis (laddering), was evident in serum-
deprived PTC3 cells while it was absent in InsGFD cells of 
both clones. Lower panel shows mean values of quantitative 
measurements of fragmented DNA in the different cell types 
under control and serum-deprived conditions. Data are mean ± 
SE of three individual experiments. *p < 0.001. 
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F i g u r e 3. Apoptosis induced by proinflammatory cytokines. 
Upper panel shows two representative gels of DNA extracted 
from InsGFD cells (clones 1 and 7) (left) and PTC3 cell (right) 
cultured for 5 days in the presence of cytokines (IL-1 50 IU/ 
ml + TNF-a 1000 Ul/ml + IFN-y 1000 Ul/ml). After exposure 
to the cytokines, DNA laddering appeared in InsGFD cell 
clones but was extremely lower than in PTC3 cells. Lower 
panel depicts quantification of DNA fragmentation, increasing 
modestly albeit significantly in InsGFD clones (*p < 0.05 vs. 
control). In contrast, cytokine-induced apoptosis was massive 
in PTC3 cells, as shown by 30% fragmented DNA. #p < 0.001 
vs. control, and *p < 0.01 vs. InsGFD of clones 1 and 7. Data 
are mean ± SE of three individual experiments. 
of 468 ± 156 pmol/L, and a gain in body weight of 6.1 
± 0 . 5 g. Mice implanted with InsGFB cells of clone 1 
showed a slower decline in blood glucose levels; 10 
weeks after transplantation mice were healthy, the aver­
age tumor diameter was 8 - 9 m m , the mean blood glu­
cose level was 148 ± 4 9 mg/dl , circulating human ma­
ture insulin was 414 ± 114 pmol /L, and the gain in body 
weight was 7.0 ± 0 . 6 g. Circulating human C-peptide, 
mature insulin, and proinsulin levels of normal nude 
mice bearing InsGH3 grafts were 0.28 ± 0.09 ng/ml , 32 
± 9 pmol /L , and 35 ± 1 1 pmol /L, respectively (n = 3). 
Northern blot analysis showed the expression of the pro­
insulin gene in InsGFB grafts of either clone 1 and 7, 
while it was negat ive in wild-type G H 3 grafts (Fig. 6, 
top). Conversely, P R L gene expression was posit ive in 
wild-type G H 3 grafts, but negat ive in InsGFB grafts of 
both clones. Note that in InsGFB cells of clone 7 the 
P R L gene expression was also low before the implanta­
tion (Fig. 6, top) . 
Graft Morphology and Immunohistochemistry 
Histology confirmed the growth of InsGH3 grafts in 
the form of encapsulated tumors with no evidence of 
capsular erosion. Hematoxyl in-eosin stain of In sGH3 
graft sections demonstra ted the presence of healthy, 
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Figure 4. Streptozotocin (STZ)-induced cell damage. Viability of InsGH3 cells (clones 1 and 7) 
and of (3TC3 cells exposed for 1 h to increasing concentrations of STZ assessed by using the MTT 
(tetrazolium) method. InsGH3 cell viability remained stable after the exposure to 10 mmol/L STZ; 
in contrast, viability of (3TC3 decreased to 55% of control values already at the lower STZ concen­
tration (2 mmol/L) and did not increased further at 10 mmol/L. Data are mean ± SE of three 
individual experiments. *p < 0.001 vs control. 
well-vascularized tissue composed of cells with small 
cytoplasms almost completely negative for insulin that, 
conversely, was extremely intense in the venules drain­
ing the grafts (Fig. 7) . Similar findings were observed 
in either c lone 1 and 7 grafts (not shown). Immunohis to­
chemistry for insulin did not show any residual (J cells 
in the pancreases of mice implanted with In sGH3 cells 
(not shown) . 
In Situ Hybridization 
Proinsulin digoxigenin-labeled R N A probes demon­
strated the expression in situ of the transfected proinsu­
lin gene in In sGH3 grafts (Fig. 8). 
D I S C U S S I O N 
The aim of cell therapy is to replace or enhance the 
biological function of damaged tissue or organs. Encap­
sulation of chromaffin cells for chronic pain (23) and 
genetically engineered immortal ized cells for neurode­
generat ive diseases have been demonstra ted exper imen­
tally and are being tested clinically (1,17). Cell therapy 
of type I diabetes relies on the replacement of the func­
tion of pancreatic (3 cells, which are selectively targeted 
and destroyed by the au to immune process responsible 
for the disease (38). Endocr ine non-p cells are an ap­
peal ing alternative for insulin gene delivery in type I 
diabetes because they might escape au to immune recog­
nition and the recurrence of graft destruction. 
In sGH3 (clones 1 and 7) grew in vitro remarkably 
faster than p T C 3 and wild-type G H 3 cells (Fig. 1). Insu­
lin might st imulate cell growth and division either by 
acting through its own receptor or the IGF-1 receptor 
(5), which is present in G H 3 cells (34). Therefore, insu­
lin might activate downstream signaling pa thways in 
InsGH3, leading to increased cell replication. The higher 
replication rate of In sGH3, compared with p T C 3 cells, 
is important because it would allow to obtain, more rap­
idly and at lower costs, a large mass of tissue for trans­
plantation in large mammals . 
Subcutaneous implantation of InsGH3 cells, pre­
viously characterized in vitro in the companion article 
(this issue), was followed by the progressive decline of 
blood glucose levels, reversal of diabetic symptoms, and 
gain in body weight in STZ-diabetic mice. Therefore, 
transplanted InsGH3 cells can process the furin-cleav-
able proinsulin gene and secrete mature human insulin 
in vivo. Moreover , circulating proinsulin and insulin lev­
els were quantitatively similar in mice bearing InsGH3 
cell grafts, in agreement with the results observed in 
vitro (see companion article). Postimplantat ion blood 
glucose reduction was faster in the recipients of InsGH3 
cells of clone 7 than of clone 1, consistent with the 
higher insulin production of the former clone detected 
in vitro (see companion article). The progressive growth 
of InsGH3 grafts (clone 7) over t ime induced hypogly­
cemia, which is an obvious drawback toward the use 
of these cells for therapeutic purposes . However , this 
problem might be overcome by encapsulation that, by 
physically restraining the cells, would limit their expan­
sion. Insulin content of transplanted InsGH3 cells was 
remarkably low, as shown by the insulin immunoreac-
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Figure 5. Upper panel shows a representative Western blot for the detection of Bcl-2 protein 
levels. Lanes from left to right are PTC3, wild-type GH3, InsGH3 clone 1, and InsGH3 clone 7. 
Lower panel depicts the densitometric analysis of different blots. Note that Bcl-2 was absent in 
pTC3 while it was relatively abundant in the other cell lines. Bcl-2 protein was significantly higher 
in InsGH3/clone 1 than in wild-type GH3 and InsGH3/clone 7. *p < 0.05. Data are mean ± SE of 
three different experiments. 
tivity of their cytoplasms. Such a reduced insulin stor­
age, together with the high plasmatic insulin levels de­
tected in the recipients, indicates that in transplanted 
InsGH3 cells the constitutive release of insulin prevails 
on the regulated secretion, perhaps more than what is 
observed in vitro (see companion article). High constitu­
tive release of insulin might put the recipient of In sGH3 
cells at risk of hypoglycemia in the postabsorptive state, 
even if the control of graft growth is achieved by encap­
sulation. Therefore, strategies a imed towards reducing 
consti tutive and possibly increasing regulated insulin se­
cretion need to be implemented before In sGH3 cells 
could be considered suitable candidates for human dia­
betes cell therapy. 
The capabili ty of transplanted InsGH3 to produce and 
release insulin is remarkable , as previous studies have 
shown that the P R L promoter activity is selectively si­
lenced in transplanted G H 3 cells (10,11). Indeed, P R L 
gene expression was undetectable in transplanted 
In sGH3, while P R L gene expression was maintained in 
transplanted wild-type G H 3 cells (Fig. 6). Lack of ex­
pression of the P R L gene by transplanted InsGH3 cells 
is an obvious advantage for our purpose. W e cannot 
make any conclusion regarding growth hormone (GH) 
graft expression nor G H serum concentrat ions, which 
were not measured in InsGH3 graft-bearing mice . 
Serum deprivation induced substantial apoptosis in 
(3TC3 cells, while it was almost ineffective on InsGH3 
cells (Fig. 2) . Cytokines induced a similar apoptotic cell 
death in (JTC3 cells, but had a limited impact on InsGH3 
cells (Fig. 3). Alterat ions in Bcl-2 m R N A and protein 
levels have been related to apoptosis induced by cyto­
kines either in M I N 6 and R I N m 5 F P-cell lines (21). The 
P-cell line (PTC1) is extremely sensitive to cytokine-
induced apoptosis that, conversely, is barely detectable 
in the a-cel l line ( a T C l ) , which is characterized by sig­
nificantly higher Bcl-2 m R N A and protein levels (29). 
Moreover , it has been recently demonstra ted that lentivi-
rus-mediated overexpression of Bcl-2 in PTC-tet cells 
significantly improves their resistance to hypoxia and 
cytokine- induced apoptosis (14). Therefore, our obser­
vation that Bcl-2 protein is relatively abundant in wild-
type G H 3 and I n s G H 3 cell clones could explain the 
resistance to apoptosis observed in InsGH3 cells, com­
pared with PTC3 cells. It should be noted that long-term 
exposure to proinf lammatory cytokines reduced I n s G H 3 
and PTC3 viability, measured by the M T T assay, to a 
similar extent, therefore suggest ing that I n s G H 3 cells 
848 D A V A L L I E T A L . 
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Figure 6. Upper panel shows a representative Northern blot hybridized with prolactin and proinsu­
lin cDNA probes. Lanes from left to right represent: |3TC3 cells, wild-type (WT) GH3, InsGH3/ 
clone 1, InsGH3/clone 7 (before transplantation for all cell types), WT GH3 graft, InsGH3/clone 
1 graft, and InsGFB/clone 7 graft. Note that the expression of the proinsulin gene was present in 
InsGFB grafts of both clones, which, in contrast, were negative for PRL gene expression. Con­
versely, PRL gene was highly expressed in WT GH3 grafts. Note also that PRL gene expression 
was already low in InsGFB cells of clone 7 before the implantation. Lower panel shows the 
glycemic levels of STZ-diabetic nude mice transplanted with either wild-type (WT) GH3 cells or 
InsGFB cells of clones 1 and 7. As expected, WT GH3 grafts did not determine any reduction in 
blood glucose levels. In contrast, mice transplanted with InsGFB cells of clone 7 showed a progres­
sive decline in blood glucose that, 4 weeks after implantation, was below the normal mouse range 
(*p < 0.05 vs. WT GH3; #p < 0.001 vs. WT GH3; %p < 0.01 vs. InsGFB of clone 1). Implantation 
of InsGFB cells of clone 1 induced a slower decrease in glycemic levels that 5 weeks later were 
still in the diabetic range even though lower than before transplantation, and of those measured in 
mice bearing WT GH3 grafts (§p < 0.02). Recipients of InsGFB/clone 1 cells were allowed to 
survive longer after transplantation, showing a progressive decrease in glycemic levels that, 10 
weeks after transplantation, reached values approaching the normal range. Data are mean + SE. 
are not protected by cytokine-mediated necrotic cell 
death. Notewor thy , InsGFB cells were also resistant to 
streptozotocin-induced cell damage . Streptozotocin acts 
either via alkylation of D N A or through the release of 
bioact ive nitric oxide (NO) (25). Whatever the cause of 
the insensitivity of InsGFB cells to STZ, such a feature 
appears as an additional advantage for transplantation 
purposes. The different response of InsGFB and p T C 3 
cells to S T Z is not explained by a differential expression 
of the glucose transporter GLUT-2 that, in other p cell 
l ines, has been pointed as the mediator of S T Z toxicity 
(35). Indeed, we did not detect G L U T - 2 protein in either 
I N S U L I N - S E C R E T I N G P I T U I T A R Y G H 3 C E L L S 
Figure 7. Histology of two adjacent sections of a InsGH3 
(clone 7) graft. On the top is a hematoxylin-eosin staining 
showing healthy cells with small cytoplasms, well vascular­
ized (arrows), and surrounded by a continuous capsule con­
taining several graft-draining venules (arrows). Lower panel 
depicts an adjacent section stained for insulin showing the al­
most complete negativity of the cellular component of the 
graft. In contrast, insulin immunoreactivity was extremely in­
tense in the venules draining the grafts. Original magnifica­
tion: x20. 
wild-type G H 3 , In sGH3, or p T C 3 cells (not shown) . The 
absence of G L U T - 2 expression by PTC3 cells, pre­
viously shown by others (30), suggests that S T Z toxicity 
involves a GLUT-2- independent pathway in p T C 3 cells. 
In conclusion, because of their elevated resistance to 
a variety of insults, InsGH3 cells appear particularly 
suited for encapsulat ion. Moreover , InsGH3 cells will 
probably also allow a greater packing density within the 
capsules as suggested by the 10-fold higher maximal 
density reached by these cells in vitro compared with 
p T C 3 cells. The achievement of physiologic regulation 
of insulin release by InsGH3 cells, and the reduction of 
their consti tutive pathway of protein secretion, will 
greatly increase the potential of these cells for transplan­
tation. 
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